In the midst of a deal spree, Bayer turns to veteran J&J dealmaker Marianne De Backer to bring home the technology
Longtime J&J dealmaker Marianne De Backer has found a new home.
Bayer put out word on Tuesday that De Backer is taking up residence as their new BD chief, right in the middle of a promised sea change in their innovation strategy.
Just weeks ago Bayer joined the high roller club in the preclinical dealmaking set, buying stem cell innovator BlueRock — or the majority interest it didn’t already own — for $240 million in cash plus $360 million in milestones. And the pharma player used that opportunity to highlight its ongoing shift in focus to external R&D as it rebuilds the pipeline.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.